Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has secured its first site to carry out the Organicell Phase I/II Multicenter, Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Zofin™ Infused Intravenous (IV) in Patients Experiencing Prolonged COVID-19 Symptoms (Long-Haulers) vs. Placebo. The site and principal investigator that will conduct the trial is Dr. Ryan Klein of NewportNativeMD in Newport Beach, California.
The trial, organized and operated through Proxima Clinical Research, a Houston-based contract research organization, is anticipated to enroll over a 12-month period with the full enrollment of 30 patients expected to be completed no later than February 2023. Based on the timing to successfully enroll all patients, Organicell plans to complete the trial no later than August 2023.
